
Gordon W Moran

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6657467/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Decreasing Colectomy Rates for Ulcerative Colitis: A Population-Based Time Trend Study. American Journal of Gastroenterology, 2012, 107, 1879-1887.	0.4	174
2	Surgical Rates for Crohn's Disease are Decreasing: A Population-Based Time Trend Analysis and Validation Study. American Journal of Gastroenterology, 2017, 112, 1840-1848.	0.4	140
3	SARS-CoV-2 vaccination for patients with inflammatory bowel disease: a British Society of Gastroenterology Inflammatory Bowel Disease section and IBD Clinical Research Group position statement. The Lancet Gastroenterology and Hepatology, 2021, 6, 218-224.	8.1	111
4	Review article: managing the adverse events caused by antiâ€TNF therapy in inflammatory bowel disease. Alimentary Pharmacology and Therapeutics, 2019, 49, 664-680.	3.7	104
5	The Increasing Weight of Crohn's Disease Subjects in Clinical Trials. Inflammatory Bowel Diseases, 2013, 19, 2949-2956.	1.9	78
6	Review: Enteroendocrine cells: Neglected players in gastrointestinal disorders?. Therapeutic Advances in Gastroenterology, 2008, 1, 51-60.	3.2	77
7	Review article: dermatological complications of immunosuppressive and anti-TNF therapy in inflammatory bowel disease. Alimentary Pharmacology and Therapeutics, 2013, 38, 1002-1024.	3.7	63
8	Phenotypic Features of Crohn's Disease Associated With Failure of Medical Treatment. Clinical Gastroenterology and Hepatology, 2014, 12, 434-442.e1.	4.4	56
9	Drug-Induced Inflammatory Bowel Disease and IBD-Like Conditions. Inflammatory Bowel Diseases, 2013, 19, 445-456.	1.9	50
10	Crohn's disease affecting the small bowel is associated with reduced appetite and elevated levels of circulating gut peptides. Clinical Nutrition, 2013, 32, 404-411.	5.0	50
11	Enteroendocrine cells in terminal ileal Crohn's disease. Journal of Crohn's and Colitis, 2012, 6, 871-880.	1.3	44
12	Review article: novel oralâ€ŧargeted therapies in inflammatory bowel disease. Alimentary Pharmacology and Therapeutics, 2018, 47, 1610-1622.	3.7	40
13	Ustekinumab for the treatment of Crohn's disease: can it find its niche?. Therapeutic Advances in Gastroenterology, 2016, 9, 26-36.	3.2	39
14	Colectomy is a risk factor for venous thromboembolism in ulcerative colitis. World Journal of Gastroenterology, 2015, 21, 1251.	3.3	37
15	Does fecal calprotectin equally and accurately measure disease activity in small bowel and large bowel Crohn's disease?: a systematic review. Intestinal Research, 2019, 17, 160-170.	2.6	35
16	Infliximab induction regimens in steroidâ€refractory acute severe colitis: a multicentre retrospective cohort study with propensity score analysis. Alimentary Pharmacology and Therapeutics, 2019, 50, 675-683.	3.7	32
17	Clinical predictors of thiopurine-related adverse events in Crohn's disease. World Journal of Gastroenterology, 2015, 21, 7795.	3.3	28
18	An Examination of Appetite and Disordered Eating in Active Crohn's Disease. Journal of Crohn's and Colitis, 2018, 12, 819-825.	1.3	26

#	Article	IF	CITATIONS
19	Assessment, endoscopy, and treatment in patients with acute severe ulcerative colitis during the COVID-19 pandemic (PROTECT-ASUC): a multicentre, observational, case-control study. The Lancet Gastroenterology and Hepatology, 2021, 6, 271-281.	8.1	23
20	<scp>MRI</scp> assessment of the postprandial gastrointestinal motility and peptide response in healthy humans. Neurogastroenterology and Motility, 2018, 30, e13182.	3.0	22
21	Systematic review: the impact of inflammatory bowel disease-related fatigue on health-related quality of life. Frontline Gastroenterology, 2021, 12, 11-21.	1.8	21
22	Literature review: impacts of socioeconomic status on the risk of inflammatory bowel disease and its outcomes. European Journal of Gastroenterology and Hepatology, 2017, 29, 879-884.	1.6	19
23	Review article: The aetiology of fatigue in inflammatory bowel disease and potential therapeutic management strategies. Alimentary Pharmacology and Therapeutics, 2021, 54, 368-387.	3.7	19
24	Crohn's disease, hepatosplenic T-cell lymphoma and no biological therapy: Are we barking up the wrong tree?. Inflammatory Bowel Diseases, 2009, 15, 1281-1282.	1.9	18
25	Reduced skeletal muscle protein balance in paediatric Crohn's disease. Clinical Nutrition, 2020, 39, 1250-1257.	5.0	17
26	Gastrointestinal peptides and small-bowel hypomotility are possible causes for fasting and postprandial symptoms in active Crohn's disease. American Journal of Clinical Nutrition, 2020, 111, 131-140.	4.7	14
27	Cine MRI assessment of motility in the unprepared small bowel in the fasting and fed state: Beyond the breathâ€hold. Neurogastroenterology and Motility, 2019, 31, e13466.	3.0	13
28	Tofacitinib in ulcerative colitis. Immunotherapy, 2016, 8, 495-502.	2.0	9
29	The Pattern of Underlying Cause of Death in Patients with Inflammatory Bowel Disease in England: A Record Linkage Study. Journal of Crohn's and Colitis, 2016, 11, jjw192.	1.3	9
30	Ustekinumab: a novel therapeutic option in Crohn's disease. Expert Opinion on Biological Therapy, 2016, 16, 1065-1074.	3.1	9
31	Diagnostic Accuracy of Non-Invasive Imaging for Detection of Colonic Inflammation in Patients with Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis. Diagnostics, 2021, 11, 1926.	2.6	9
32	Imaging in inflammatory bowel disease: current and future perspectives. Frontline Gastroenterology, 2022, 13, e28-e34.	1.8	9
33	Acetarsol Suppositories: Effective Treatment for Refractory Proctitis in a Cohort of Patients with Inflammatory Bowel Disease. Digestive Diseases and Sciences, 2018, 63, 1011-1015.	2.3	8
34	Clinical utility of small bowel ultrasound assessment of Crohn's disease in adults: a systematic scoping review. Frontline Gastroenterology, 2022, 13, 280-286.	1.8	8
35	Ultrasound use to assess Crohn's disease in the UK: a survey of British Society of Gastroenterology Inflammatory Bowel Disease Group members. Frontline Gastroenterology, 2022, 13, 471-476.	1.8	8
36	Acetarsol in the management of mesalazine-refractory ulcerative proctitis: a tertiary-level care experience. European Journal of Gastroenterology and Hepatology, 2019, 31, 183-186.	1.6	7

GORDON W MORAN

#	Article	IF	CITATIONS
37	Survey to define informational needs of patients undergoing surgery for Crohn's anal fistula. Colorectal Disease, 2021, 23, 132-144.	1.4	7
38	MR Measures of Small Bowel Wall T2 Are Associated With Increased Permeability. Journal of Magnetic Resonance Imaging, 2021, 53, 1422-1431.	3.4	7
39	Orbital Inflammatory Complications of Crohn's Disease: A Rare Case Series. Clinical Medicine Insights Gastroenterology, 2018, 11, 117955221875751.	1.0	6
40	Experiences of using vedolizumab in the treatment of inflammatory bowel disease in the East Midlands UK – a retrospective observational study. Scandinavian Journal of Gastroenterology, 2020, 55, 907-916.	1.5	6
41	Practice pattern variability in the management of acute severe colitis: a UK provider survey. Frontline Gastroenterology, 2020, 11, 272-279.	1.8	6
42	Simultaneous Measurement of Gastric Emptying of a Soup Test Meal Using MRI and Gamma Scintigraphy. Diagnostics, 2020, 10, 170.	2.6	6
43	Evolution of treatment targets in Crohn's disease. Bailliere's Best Practice and Research in Clinical Gastroenterology, 2019, 38-39, 101599.	2.4	4
44	Test–retest assessment of non-contrast MRI sequences to characterise and quantify the small bowel wall in healthy participants. Magnetic Resonance Materials in Physics, Biology, and Medicine, 2021, 34, 791-804.	2.0	4
45	Skeletal muscle anabolic and insulin sensitivity responses to a mixed meal in adult patients with active Crohn's disease. Clinical Nutrition ESPEN, 2021, 41, 305-313.	1.2	3
46	Establishment of a validated central reading system for ileocolonoscopy in an academic setting. Gut, 2022, 71, 661-664.	12.1	3
47	Current Use of EEN in Pre-Operative Optimisation in Crohn's Disease. Nutrients, 2021, 13, 4389.	4.1	3
48	Inflammatory bowel disease clinical service recovery during the COVID-19 pandemic. Frontline Gastroenterology, 2022, 13, 77-81.	1.8	2
49	Quantitative Magnetic Resonance Imaging in Perianal Crohn's Disease at 1.5 and 3.0 T: A Feasibility Study. Diagnostics, 2021, 11, 2135.	2.6	2
50	Acute effects of prior dietary fat ingestion on postprandial metabolic responses to protein and carbohydrate co-ingestion in overweight and obese men: A randomised crossover trial. Clinical Nutrition, 2022, 41, 1623-1635.	5.0	2
51	Acute dysphagia after a normal endoscopy: think outside the box. Clinical Medicine, 2013, 13, 315-316.	1.9	1
52	The impact of Inflammatory Bowel Disease related fatigue on Health-Related Quality of Life: a qualitative semi-structured interview study. Journal of Research in Nursing, 2022, 27, 685-702.	0.9	1
53	Myelofibrosis, Splenomegaly, and Upper Gastrointestinal Hemorrhage: An Unusual Link. Clinical Gastroenterology and Hepatology, 2008, 6, A24.	4.4	0
54	Anaemia in a cardiopath: Figure 1. Gut, 2012, 61, 513-513.	12.1	0

#	Article	IF	CITATIONS
55	Letter: dermatological complications with therapy for inflammatory bowel disease – authors' reply. Alimentary Pharmacology and Therapeutics, 2014, 39, 233-234.	3.7	0
56	PWE-041â€Alteration in small bowel motility, gut peptides and patient's symptoms in active crohn's disease. , 2018, , .		0
57	Physical activity and fatigue in adults with inflammatory bowel disease (IBD): a systematic review. Gastrointestinal Nursing, 2019, 17, 16-21.	0.1	0